Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reported at the ASCO congress.

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

If approved, Kisqali could nearly double the number of patients eligible for CDK4/6 inhibitor adjuvant therapy," said Patrick Horber M.D., President, International, Novartis. "Together with the ...

The NCCN has updated its breast cancer guidelines, designating Novartis' Kisqali as a Category 1 preferred CDK4/6 inhibitor ...

Novartis’ Kisqali (ribociclib) has been recommended by the European Medicines Agency’s human medicines committee to reduce the risk of recurrence in early breast cancer patients. The Committee for ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...

If approved, Kisqali could nearly double the number of patients eligible for CDK4/6 inhibitor adjuvant therapy," said Patrick Horber M.D., President, International, Novartis. "Together with the recent ...

Recommendation is based on the Phase III NATALEE trial, where Kisqali added to endocrine therapy (ET) significantly reduced the risk of recurrence by 25% versus ET alone across a broad population ...

Basel, October 18, 2024 – Novartis announced today that the Committee ... and recommended granting marketing authorization for Kisqali ® (ribociclib) for the adjuvant treatment of adults ...